Pharma Focus Europe

Toragen, Inc. Releases Positive Safety Update for First Cohort of Phase 1 Trial in Individuals with Human Papillomavirus-Induced Cancer

Tuesday, November 07, 2023

Today, Toragen Inc., a San Diego-based biotechnology company specializing in the development of selective drugs for cancers caused by viruses, has reported positive safety findings from Cohort 1 of its Phase 1 trial of TGN-S11. This marks Toragen's first drug candidate for patients with HPV-associated cancers.

The Phase 1 trial is an open-label, non-randomized study that involves cohorts of patients with relapsed, resistant, or metastatic HPV-associated cancers. The trial consists of two parts: a dose escalation phase and a dose expansion phase. The dose escalation phase includes five cohorts, each consisting of three to six patients. If Cohorts 1 and 2 in the escalation phase are found to be safe and well-tolerated, the dose expansion phase will commence with a dose level slightly lower than the highest safe and well-tolerated dose, in combination with a PD-1 checkpoint inhibitor.

Dr. Sandra Coufal, CEO of Toragen, emphasized, "There is a significant medical need for treatments targeting HPV-associated cancers. Current treatments for these cancers are limited, and we are excited to provide Toragen's clinical trial as an option. Although the data is preliminary, based only on Cohort 1, we have observed favorable safety and tolerability, and we eagerly anticipate enrolling more patients in our trial."



Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024